|
| |
 |
|
| CASE REPORT |
|
| Year : 2022 | Volume
: 12
| Issue : 4 | Page : 235-238 |
|
Pulmonary embolism in patients with severe COVID-19 treated with systemic low-dose thrombolytic therapy: A case series
I Gusti Ngurah Mahaalit Aribawa1, Christopher Ryalino1, Adinda Putra Pradhana1, Putu Utami Dewi2, Cyndiana Widia Dewi Sinardja3, Ni Kadek Mulyantari4
1 Department of Anesthesiology and Intensive Care, Udayana University Hospital, Denpasar, Indonesia
2 Department of Radiology, Udayana University Hospital, Denpasar, Indonesia
3 Department of Cardiology, Udayana University Hospital, Denpasar, Indonesia
4 Department of Clinical Pathology, Udayana University Hospital, Denpasar, Indonesia
| Date of Submission | 24-Jul-2022 |
| Date of Acceptance | 22-Sep-2022 |
| Date of Web Publication | 26-Dec-2022 |
Correspondence Address:
Dr. I Gusti Ngurah Mahaalit Aribawa
Department of Anesthesiology and Intensive Care, Udayana University Hospital, Jl. Rumah Sakit Unud, Bali, 80361
Indonesia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijciis.ijciis_53_22
 Abstract | | |
Coronavirus disease 2019 (COVID-19) has been associated with respiratory failure and high mortality. Hypercoagulability and thromboembolic complications have been found in a high percentage of patients amongst which, pulmonary embolism (PE) is the most common. Currently, there are no guidelines on using thrombolysis therapy in COVID-19 patients who developed PE. We present five survivors aged 30–75 years old with confirmed COVID-19. All cases were proven by computed tomography pulmonary angiogram (CTPA) to have PE treated with low-dose recombinant tissue plasminogen activator (rtPA). PE should be suspected in all COVID-19 patients with rapid worsening of dyspnea, desaturation, unexplained shock, and increased level of D-dimer and fibrinogen. In our cases, PE developed despite preventative anticoagulation regimens with low molecular weight heparin. After thrombolytic therapy, all patients showed improvement in partial-arterial-oxygen-pressure to inspired oxygen-fraction ratio (arterial partial pressure of oxygen/inspired oxygen fraction ratio). D-dimer showed elevation after thrombolytic therapy and decreased in the following days. Fibrinogen levels decreased following thrombolytic therapy. Current anticoagulation regimens seem insufficient to halt the course of thrombosis, and thrombolytic therapy may be beneficial for patients with severe COVID-19 and PE. Systemic thrombolysis therapy is a double-edged sword, and clinicians must balance between benefit and risk of bleeding.
Keywords: Alteplase, case series, coronavirus disease 2019, pulmonary embolism, thrombolytic
How to cite this article:
Aribawa I G, Ryalino C, Pradhana AP, Dewi PU, Sinardja CW, Mulyantari NK. Pulmonary embolism in patients with severe COVID-19 treated with systemic low-dose thrombolytic therapy: A case series. Int J Crit Illn Inj Sci 2022;12:235-8 |
How to cite this URL:
Aribawa I G, Ryalino C, Pradhana AP, Dewi PU, Sinardja CW, Mulyantari NK. Pulmonary embolism in patients with severe COVID-19 treated with systemic low-dose thrombolytic therapy: A case series. Int J Crit Illn Inj Sci [serial online] 2022 [cited 2023 Jan 29];12:235-8. Available from: https://www.ijciis.org/text.asp?2022/12/4/235/364744 |
| Introduction | |  |
Coronavirus disease 2019 (COVID-19) is a disease caused by the severe acute respiratory syndrome coronavirus-2 that was first reported in Wuhan, China, in December 2019.[1] The clinical presentation varies between asymptomatic infection, mild respiratory infection, and severe pneumonia with respiratory failure and death. Patients with severe COVID-19 may experience features of systemic inflammation or cytokine storm and coagulopathy. This has been confirmed in larger studies, with nearly 50% of COVID-19 patients demonstrating elevated D-dimer and fibrin degradation products, with the degree of elevation correlating with illness severity in cohorts.[2]
A study in Spanish population showed that the incidence of pulmonary embolism (PE) in COVID-19 patients was 4.92%, or ninefold higher compared to non-COVID population.[3] The study found immobilization and congestive heart failure (CHF) are risk factors of PE in COVID-19. Another publication has documented severe hemostatic derangement using whole blood thromboelastography, resulting in a hypercoagulable state.[4] This may result in thromboembolic complications, the most common of which is PE.
PE is known to lead to significant morbidity and mortality and treating it could lead to marked clinical improvement. A review about PE in COVID-19 cases reported that there was no detectable origin of PE in 80% of COVID-19 cases and that PE was diagnosed at 11 days after the onset of COVID-19.[5] The review also stated that 10% died despite thrombolytic treatment, recombinant tissue plasminogen activator (rtPA), or full-dose low molecular weight heparin therapy.
| Case Reports | | |
Case 1
A 75-year-old male known hypertensive presented with dyspnea, rales on both lungs, and fever of 12-day duration. Demographics and case details are presented in [Table 1]. He was also confirmed for COVID-19 from nasopharyngeal swab by reverse transcription polymerase chain reaction (RT-PCR) test. He complained of worsening breathlessness the next day and his peripheral oxygen saturation (SpO2) dropped to 87%. His respiratory rate (RR) was 35–40 per minute, blood pressure (BP) 145/71 mmHg, heart rate (HR) 120 bpm, and he was anxious. Arterial blood gas (ABG) showed partial pressure of oxygen (pO2) 78 mmHg and partial pressure of carbon dioxide (pCO2) 48.2 mmHg (under 80% inspired oxygen fraction [FiO2]). A computed tomography pulmonary angiogram (CTPA) identified pulmonary emboli as described in [Table 2]. Thrombolytic therapy was given using intravenous (IV) alteplase 5 mg over 2 h followed by 45 mg in the next 22 h, which resulted in improved saturation and ABG. Two days later, he again desaturated to 85% with increased D-dimer (3417 ng/ml) and worsening ABG. We administered a second dose of IV alteplase with similar dose, resulting in improved clinical condition without re-bleeding episode. | Table 2: Summary of computed tomography pulmonary angiogram findings in our cases
Click here to view |
Case 2
A 54-year-old male with no comorbidities presented with dyspnea and fever for 3 days. He tested positive for COVID-19 via RT-PCR. Physical examination showed RR 30–35 per minute, BP 121/73 mmHg, HR 105–110 bpm, and SpO2 of 90%. We managed this case aggressively without waiting for deterioration signs by providing high-flow nasal cannula at 30 L/minutes flow and FiO2 80%. ABG showed pH 7.369, pCO2 42.0 mmHg, and pO2 108 mmHg. His D-dimer level was 1606 ng/mL. CTPA revealed thrombosis on distal branches of the right pulmonary vein [Table 2]. We administered IV alteplase (5 mg over 2 h followed by 45 mg over the next 22 h) and subcutaneous enoxaparin 60 mg 12-hourly afterward. His vital signs remained stable, and no bleeding was noted. After 16 days in intensive care, he was discharged home.
Case 3
A 38-year-old female with confirmed COVID-19 with no comorbidities was admitted to isolation on the 9th day of symptoms (fever and severe coughing). She deteriorated and was transferred to the intensive care unit (ICU) after 3 days of treatment. Her RR was 24–28 per minute, BP 135/75 mmHg, and HR 80–85 bpm. She developed atypical chest pain, shortness of breath, lightheadedness, and desaturated to 70% (under 100% FiO2) after 11 days of ICU treatment. After confirming the presence of PE by CTPA [Table 2], we started a more aggressive therapy using IV alteplase 25 mg over 2 h followed by continuous infusion of 25 mg over the next 22 h. Superficial bleeding was noted. Her condition improved and she was discharged home 22 days after hospitalization.
Case 4
A 35-year-old female was referred with fever and shortness of breath for 9 days. Besides COVID-19 positive, she also had a history of hypertension and CHF. On the 6th day of ICU treatment, she experienced several intermittent episodes of desaturation (down to 80%), tachypnea (45 breaths per minute), tachycardia (120–130 bpm), and intermittent mild hemoptysis. Laboratory analysis revealed pH 7.498, pCO2 37.3 mmHg, pO2 51 mmHg, and D-dimer 2,498 ng/dL. After confirming with CTPA [Table 2], IV alteplase was started immediately with a dosage of 30 mg over 2 h and continued with 50 mg over the next 22 h. A larger dose was deemed required due to her obese condition. Hematuria was noted during alteplase administration but improved after alteplase was finished. Her condition was gradually improved, and she was moved to ward after 20 days in ICU. She was then discharged home 6 days later.
Case 5
A 30-year-old male with no other medical history presented with dyspnea for 3 days. Upon ICU admission, with a confirmed COVID-19 RT-PCR result, he complained about sudden palpitations and dizziness, his RR was 35–40 per minute, HR 95–100 bpm, BP 143/106 mmHg, and SpO2 96%. Initial blood gas analysis showed pH 7.42, pCO2 36 mmHg, and pO2 83 mmHg. On the 7th day of ICU treatment, his D-dimer increased to 2866 ng/ml and SpO2 dropped to 85%. After CTPA confirmation of PE, we initiated alteplase 25 mg over 2 h and continued with 25 mg over the next 22 h. No bleeding was noted. Clinical improvement was noted after alteplase, and although D-dimer level was increased to 5310 ng/ml on the next day, it decreased to 827 ng/ml 2 days after. He was discharged after 10 days of treatment in hospital.
| Discussion | | |
The current guideline suggests the use of systemic thrombolysis in patients who are at high risk of developing PE.[5] In patients with intermediate-risk PE, thrombolytic therapy with standard dosage of rtPA was associated with a significant reduction in the risk of hemodynamic decompensation but was paralleled by an increased risk of severe bleeding.
Tissue plasminogen activator is one of the essential components in the dissolution of blood clots. Its primary function is to convert plasminogen to plasmin, the primary enzyme involved in dissolving blood clots by breaking up the molecules of fibrin. Examples of these drugs are alteplase, urokinase, streptokinase, reteplase, and tenecteplase. Alteplase is the biosynthetic form of human plasminogen activator and is approved by the United States Food and Drug Administration for managing ischemic stroke, ST-elevation myocardial infarction, and PE.[6]
The standard dosage of alteplase for PE is 100 mg over 2 h.[6] A recent report compared the 100 mg/2 h and 50 mg/2 h regimens which found that the reduced dosage exhibits similar efficacy and perhaps better safety profile.[7] Another case series used rtPA for sub-massive PE using 10 mg IV bolus over 1 min and continued with 40 mg IV over 2 h.[8]
Currently, there is no guideline in using thrombolysis therapy in COVID-19 patients who developed PE. A French study[9] reported seven cases using rtPA in COVID-19 patients with PE, with standard protocol of 10 mg over 15 min, and continued with 90 mg over 120 min. They reported a reduced Brescia-COVID Respiratory Severity Scale in all patients and no major bleeding events.
Alteplase was associated with an increased risk of severe bleeding, with up to 20.6% of patients experiencing major bleeding and 7.4% experiencing intracranial bleeding.[10] Because of this, we used a lowered dose of rtPA in our patients. Case 1 had bleeding from a central venous catheter insertion site, case 3 had superficial bleeding from the enoxaparin injection site, and case 4 had hematuria. All bleedings were conservatively managed. None of our patients had evidence of intracranial bleeding.
While this case series presents the effectiveness of low-dose rtPA in our patients, there are several limitations that need to be acknowledged. First, this case series only showed success in five patients with CTPA-proven PE. Second, the regimen used was not homogenous, and the decision was mainly clinically based. Third, no CTPA or echocardiography evaluation was done after thrombolytic therapy. Although the clinical improvement is substantial, we still need to prove the resolution of thrombosis by imaging studies.
| Conclusion | | |
Systemic thrombolysis therapy is a double-edged sword and clinicians must balance benefits with risk of bleeding. Our case series provides examples of using low-dose rtPA with excellent result and minimal complication. Nevertheless, we are not sure whether this regimen could be generalized to all COVID-19 patients with PE, and larger studies are needed to determine the best possible treatment and construct better guidelines.
Research quality and ethics statement
This case report did not require approval by the Institutional Review Board/Ethics Committee. The authors followed the applicable EQUATOR Network (http://www.equator-network.org/) guideline, specifically the CARE guideline, during the conduct of this research project.
Declaration of patient consent
The authors certify that each subject provided written informed consent for the publication of de-identified findings, but that anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Ryalino C. Covid-19: What we know so far. Bali J Anaesthesiol 2020;4:1-2.  [Full text] |
| 2. | Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844-7. |
| 3. | Miró Ò, Jiménez S, Mebazaa A, Freund Y, Burillo-Putze G, Martín A, et al. Pulmonary embolism in patients with COVID-19: Incidence, risk factors, clinical characteristics, and outcome. Eur Heart J 2021;42:3127-42. |
| 4. | Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020;18:1738-42. |
| 5. | Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: A consensus statement before guidelines. Thromb Haemost 2020;120:937-48. |
| 6. | |
| 7. | Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: A randomized, multicenter, controlled trial. Chest 2010;137:254-62. |
| 8. | Nguyen PC, Stevens H, Peter K, McFadyen JD. Submassive pulmonary embolism: Current perspectives and future directions. J Clin Med 2021;10:3383. |
| 9. | Philippe J, Cordeanu EM, Leimbach MB, Greciano S, Younes W. Acute pulmonary embolism and systemic thrombolysis in the era of COVID-19 global pandemic 2020: A case series of seven patients admitted to a regional hospital in the French epidemic cluster. Eur Heart J Case Rep 2021;5:ytaa522. |
| 10. | Daley MJ, Murthy MS, Peterson EJ. Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: Scope of the problem. Ther Adv Drug Saf 2015;6:57-66. |
[Table 1], [Table 2]
|
